What Is Pepsin —
and Why Does It Matter in Reflux?
Most people with LPR are told their problem is acid. The research tells a different story. Pepsin — the digestive enzyme your stomach produces — is the primary agent of damage in silent reflux. Understanding this single fact changes everything about how LPR is diagnosed and treated.
CE-IVD certified saliva test · No GP referral required · Home collection kit
What Is Pepsin?

Pepsin is a digestive enzyme produced in the stomach. Its job is to break down proteins in food — it is one of the primary tools your body uses to digest a meal. In the stomach, where it belongs, it is essential. The problem begins when it ends up somewhere it shouldn't be.
Pepsin is made from an inactive precursor called pepsinogen, which is secreted by specialised cells in the stomach lining called chief cells. When stomach acid drops the pH low enough — below about 6 — pepsinogen converts into its active form: pepsin. In the acidic environment of the stomach (typically pH 1.5–3.5), pepsin is highly active and gets on with the business of digesting protein.
Here is the critical point: the stomach is designed to contain pepsin. The oesophagus, throat, larynx, and airways are not. They lack the protective mucus lining that shields the stomach from its own digestive chemistry. When pepsin reaches these tissues via reflux, the damage it causes is quite different from the burn of stomach acid — and in many ways, more persistent.
- Produced by chief cells in the stomach lining
- Converted from inactive pepsinogen when pH falls below ~6
- Active digestive enzyme in the stomach at pH 1.5–3.5
- Remains stable (doesn't break down) at pH 7.4 — the pH of the larynx
- Remains enzymatically active up to pH 6.5
- Primary agent of tissue damage in LPR, not acid
- Can be detected in saliva — the basis of the Peptest diagnostic
Pepsin & LPR: The Discovery That Changed Everything
For most of the 20th century, reflux was understood as an acid problem. The symptoms it caused in the throat — chronic cough, hoarseness, a persistent lump sensation — were attributed to acid reaching the larynx and burning the tissue. It was a reasonable assumption, and it underpinned decades of treatment: suppress the acid with proton pump inhibitors (PPIs), and the symptoms should resolve.
But for many patients — particularly those with laryngopharyngeal reflux (LPR) — they didn't. Something else was going on.
The key breakthrough came from work conducted jointly by Professor Peter Dettmar, founder of RD Biomed and a pioneering researcher at the University of Hull, and Dr Nikki Johnston at the Medical College of Wisconsin, who leads the Pepsin and Reflux Laboratory there. Their landmark 2007 paper in the journal Laryngoscope established something that fundamentally changed the field: pepsin is stable at a pH of 7.4, and remains enzymatically active — capable of breaking down tissue — at a pH as high as 6.5.
This matters enormously. The larynx sits at approximately pH 7.4 — a neutral, physiologically normal environment for the tissues there. But it is a perfectly hospitable environment for pepsin. When pepsin arrives in the larynx via a reflux event, it does not deactivate. It does not break down. It persists. And at pH 6.5 — which is easily reached in the larynx after eating acidic foods or during mild irritation — it is still capable of causing enzymatic damage.
Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope. 2004. — and subsequent stability/activity studies confirming pepsin remains stable at pH 7.4 and active to pH 6.5. Published in Laryngoscope, 2007. This research established pepsin, not acid, as the primary agent of laryngeal damage in LPR.
Prior to this work, the clinical model was straightforward: acid rises, acid burns, acid suppression solves the problem. The Johnston–Dettmar findings introduced a more complex and more accurate picture: acid carries pepsin upward during reflux, but even when the acid dissipates — or is pharmacologically suppressed — the pepsin remains. And it is still capable of doing damage.
This is the scientific foundation on which Peptest is built. If pepsin is the active agent, then detecting pepsin is the logical way to diagnose LPR. It is also the foundation for understanding why so many LPR patients remain symptomatic despite taking PPIs faithfully.
Inside the Cell: How Pepsin Causes Lasting Damage
If you have LPR, you might have wondered why your throat symptoms persist for hours — or days — after what you suspect was a reflux event. The reason lies in something that happens at the cellular level, and it helps explain why LPR is so difficult to treat with acid-suppressing medication alone.
Here is the plain-English version of what happens: when pepsin arrives on the surface of the laryngeal lining, the cells there don't just sit passively. They actively take it in. The pepsin is absorbed inside the cell — and once inside, it finds an environment acidic enough to reactivate and begin causing damage from within.
The scientific name for this process is receptor-mediated endocytosis, and it was established through the research of Dr Nikki Johnston, published in the Annals of Otology, Rhinology and Laryngology in 2007. Here is what the mechanism looks like in detail:
Pepsin Reaches the Larynx
During a reflux event, stomach contents — including pepsin — travel up through the oesophagus and reach the larynx and pharynx. The acidic conditions that activate pepsin may be brief or mild, but the pepsin itself persists.
Cells Absorb the Pepsin
Laryngeal epithelial cells take up pepsin via receptor-mediated endocytosis — a normal cellular process usually used to absorb nutrients and signalling molecules. The cells, in effect, mistake pepsin for something they should be absorbing.
Reactivation Inside the Cell
Inside the cell, pepsin is trafficked to compartments called endosomes. Endosomes are naturally acidic — pH around 5 — and at pH 5, pepsin reactivates. It is now inside the cell, active, and beginning to digest the cellular structures around it.
Intracellular Damage
The research documents specific patterns of cellular injury: mitochondrial swelling (disrupting the cell's energy production), depletion of E-cadherin (a protein that holds cells together and maintains the integrity of the tissue barrier), and activation of stress genes. These changes represent genuine structural damage — not just inflammation.
Johnston N et al. Cell biology of laryngeal epithelial defenses in health and disease: further studies. Ann Otol Rhinol Laryngol. 2007. — Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012. Together these papers document the endocytosis mechanism, intracellular trafficking, reactivation at pH 5, and the specific patterns of cellular damage observed.
The clinical implication of this mechanism is significant: once pepsin is inside the cell, it is entirely beyond the reach of anything happening in the stomach. You can suppress gastric acid completely — and the pepsin that has already been internalised by laryngeal cells will still cause damage. This is one of the core reasons why PPIs, which work by reducing acid production in the stomach, provide incomplete relief for so many LPR patients.
There is a further dimension worth noting. Research by Kelly, Samuels and Johnston (2014) explored the relationship between pepsin and cancer risk. The finding that pepsin can activate cellular stress pathways and cause sustained intracellular damage raises the question of long-term consequences for repeatedly exposed laryngeal tissue. While this remains an area of ongoing investigation, it adds weight to the clinical importance of identifying and managing LPR accurately — not merely managing its symptoms.
Dietary Acid Reactivation: Why Your Morning Coffee Triggers Symptoms
One of the most confusing — and frustrating — aspects of LPR is this: symptoms can appear hours after eating, without any obvious reflux event. A patient might wake with a clear throat, eat breakfast, drink a coffee, and then find their hoarseness or throat-clearing returns within the hour. It can seem completely disconnected from reflux. It isn't.
The explanation lies in what we know about pepsin stability. Pepsin deposited on laryngeal tissue during a reflux event — even one that happened hours earlier — doesn't simply disappear. At the neutral pH of the larynx (pH 7.4), it becomes inactive but structurally intact. It is waiting, in effect, for conditions to change.
When you drink coffee (pH approximately 5), orange juice (pH 3.5–4), a carbonated drink, or eat citrus fruit, the pH in the pharynx and larynx drops temporarily. This is enough to reactivate pepsin that has been sitting dormant on the mucosal surface. No new reflux is required. The acidic food or drink is doing the reactivating work itself.
This is why dietary modification is clinically important in LPR management — not simply because acidic foods irritate inflamed tissue (though they do), but because they can reactivate the enzymatic process that caused the damage in the first place. It also explains why some patients notice that avoiding acidic foods and drinks gives them more relief than their PPI prescription.
Understanding this mechanism can also make symptom patterns make more sense. If you track your LPR symptoms and notice they flare after coffee, citrus, wine, or sparkling water — especially if the timing feels too delayed to be a direct reflux response — dietary reactivation of deposited pepsin is the likely explanation.
For a full breakdown of which symptoms this mechanism produces and why they appear in the throat rather than the chest, see our detailed LPR symptoms guide →
Important: Acidic drinks can trigger symptoms without new reflux
Pepsin deposited on laryngeal tissue during a previous reflux event can be reactivated hours later by acidic food and drink — coffee, citrus juice, fizzy drinks, wine. This is distinct from causing a new reflux event. It is why avoiding acidic foods and drinks is an important part of LPR management, not just general dietary advice.
Why PPIs Often Fall Short for LPR
Proton pump inhibitors — omeprazole, lansoprazole, esomeprazole and their relatives — are among the most commonly prescribed medications in the world. They work by blocking the proton pumps in the stomach lining that produce gastric acid. For GERD, where acid is the primary damaging agent, they are often highly effective. For LPR, the picture is considerably more complicated.
The science described above explains why. PPIs reduce acid production. What they do not do is prevent pepsin from being carried upward during reflux events. Non-acidic, or weakly acidic, reflux — sometimes called non-acid reflux — still carries pepsin into the oesophagus and larynx. PPIs have no effect on this.
Furthermore, as the endocytosis research makes clear, once pepsin has been internalised by laryngeal cells, it is operating in a compartment that PPI therapy cannot reach. The drug acts in the stomach. The damage is occurring inside cells in the throat. These are different locations, separated by a physiological gap that pharmacology has not yet crossed — except, as we will see in the next section, potentially through pepsin-inhibiting drugs now in clinical trials.
The clinical evidence supports this mechanistic reasoning. A 2013 study by Crossfield and colleagues found that pepsin remains detectable in the airways of patients with chronic cough despite PPI therapy. The patients were taking their medication as prescribed, their acid was being suppressed, and pepsin was still present and still active. This is not a failure of the medication — it is doing what it was designed to do. It is simply not designed to address pepsin.
None of this means PPIs are without value in LPR. They reduce the volume of acidic material available to be refluxed, they may reduce the severity of some reflux events, and they are appropriate in many combined GERD/LPR presentations. The point is not that PPIs are wrong, but that they are insufficient as the sole treatment for LPR — and that patients who remain symptomatic despite PPI therapy should not conclude that their symptoms must therefore not be reflux.
What PPIs Do
- ✓ Reduce gastric acid production
- ✓ Reduce acidity of refluxate
- ✓ Effective for oesophageal GERD
- ✗ Do not reduce pepsin in refluxate
- ✗ Do not prevent non-acid reflux events
- ✗ Cannot reach pepsin internalised in cells
- ✗ Pepsin remains detectable despite PPI use
What the Pepsin Mechanism Requires
- → Reducing the volume of reflux events
- → Alginate barrier therapy (Gaviscon Advance)
- → Dietary acid avoidance (prevents reactivation)
- → Positional and lifestyle changes
- → Direct detection to confirm LPR is active
- → Future: pepsin-inhibiting drugs (fosamprenavir)
For a full guide to LPR treatment — including alginate therapy, dietary modification, and emerging options — see our dedicated LPR treatment guide → . For patients whose symptoms persist despite treatment, retesting with Peptest can confirm whether pepsin is still present and reflux remains active.
Pepsin as a Biomarker: Why Detecting It Makes Clinical Sense
If pepsin is the primary agent of damage in LPR, then the logical approach to diagnosis is to look for pepsin. Not acid. Not the symptoms acid might cause. Pepsin — the molecule that should not be present in the throat, that is stable and detectable when it gets there, and whose presence in saliva or laryngeal secretions is the most direct evidence that reflux has occurred and that the primary damaging agent is active.
This is the scientific rationale behind Peptest. Saliva is collected shortly after symptoms occur — or at times when reflux is statistically most likely (for example, after a meal). The sample is tested using an antibody specific to human pepsin. If pepsin is present at a clinically meaningful concentration, the test is positive. If it is not, the test is negative.
What makes pepsin a particularly strong biomarker for LPR is the property we have already described: its stability. Pepsin persists in laryngeal and pharyngeal tissue long enough to be captured in a saliva sample, even if the reflux event that deposited it occurred some time earlier. A test based on detecting acid — an inherently transient substance — would need to be performed immediately during an event. A test based on detecting pepsin can be performed in a meaningful window after the event, making home-based collection practicable.
The largest published study of Peptest — conducted by Dettmar and colleagues in 2019 across five NHS voice clinics with 1,033 patients — demonstrated 100% specificity. Every positive Peptest result was confirmed as true reflux. There were no false positives. Sensitivity ranged from 73–87% across published studies, with a 2023 Vietnamese study of 149 patients reporting 87% sensitivity. The test does not catch every case of LPR, but when it is positive, clinicians and patients can have high confidence in the result.
That evidence base has since been independently corroborated at the pooled-study level. A 2025 meta-analysis published in Neurogastroenterology & Motility — aggregating data across multiple studies — reported a diagnostic odds ratio of 7.03 for salivary pepsin, with 73% sensitivity and 72% specificity, and an area under the ROC curve of 0.79. A diagnostic odds ratio above 7 indicates strong discriminatory power between those with and without reflux. The consistency between individual study figures and the pooled meta-analysis findings reinforces that salivary pepsin detection is a reproducible, clinically meaningful biomarker — not an artefact of any single study design. Read our summary of the Neurogastroenterology & Motility meta-analysis →
For patients who have been told their symptoms "don't look like reflux," or who have tried PPIs without success and are wondering whether reflux is really the cause, Peptest offers a direct, non-invasive answer. It doesn't infer reflux from symptoms or pH readings — it detects the primary damaging agent itself, in the biological material where it appears.
To understand the full range of diagnostic options for LPR — including how Peptest compares to RSI scoring, laryngoscopy, and pH monitoring — see our detailed LPR diagnosis guide →
The Future of LPR Treatment: Fosamprenavir & N-Zyme Biomedical
If pepsin — not acid — is the primary therapeutic target in LPR, the logical consequence is a drug that inhibits pepsin directly. Until recently, no such drug existed for clinical use. That is changing.
Dr Nikki Johnston — the same researcher whose endocytosis work established the mechanism described in this page — co-founded N-Zyme Biomedical alongside Franco Vigile specifically to develop the world's first pepsin-inhibiting drug. The compound they are advancing through clinical trials is fosamprenavir, originally developed as an HIV protease inhibitor. Protease inhibitors work by blocking the active sites of enzymes — and pepsin, being a protease, has an active site that fosamprenavir is capable of blocking.
In a 2023 study published in Laryngoscope, Johnston and colleagues reported in vivo validation of fosamprenavir as a pepsin inhibitor. The drug was shown to inhibit pepsin activity in a living model — a critical step in the clinical development pathway. This is not a speculative compound: it is an existing, approved drug with a known safety profile, being repurposed for a new application with strong mechanistic rationale.
Phase II clinical trials are currently underway. If successful, fosamprenavir would represent the first therapeutic directly targeting the molecular mechanism of LPR damage — rather than managing the acid environment that carries pepsin upward. The significance of this cannot be overstated: it would validate, at the pharmaceutical level, the entire framework that Professor Dettmar and Dr Johnston's research established over the preceding two decades. Pepsin is the target. Pepsin is the problem. And pepsin can, in principle, be inhibited.
N-Zyme Biomedical is developing the world's first pepsin-inhibiting therapeutic, based on the research of Dr Johnston at the Medical College of Wisconsin. Fosamprenavir — repurposed from HIV treatment — has been validated in vivo as a pepsin inhibitor and is in Phase II clinical trials for LPR.
Visit nzymebio.com →For patients living with LPR today, the clinical trials represent genuine reason for optimism — but they are not yet available as a treatment. For a closer look at the science behind fosamprenavir and what the trials involve, see our fosamprenavir and LPR treatment blog post. In the meantime, the best available approach combines accurate diagnosis (knowing whether pepsin is actually present), barrier therapy with alginate, dietary modification to prevent reactivation, and lifestyle changes that reduce reflux frequency. That framework — grounded in the same science — remains the current standard of care.
Peptest sits within that framework: as the most direct available method for confirming whether LPR is active, monitoring treatment response, and giving patients and clinicians the information they need to manage the condition appropriately.
Know Whether Pepsin Is Active in Your Throat
If you want to know whether pepsin is present in your throat right now — not inferred from symptoms, but directly detected — Peptest does exactly that. A simple saliva test, completed at home, with results in 48 hours. No GP referral required.
Order Peptest £79.95 · Free UK Delivery · Results in 48hrsCE-IVD certified · UK laboratory, Hull · 40+ countries · +44 (0)1482 935020